IVISense™ Hypoxia CA IX 680 (HypoxiSense™ 680) is a carbonic anhydrase IX (CA IX) targeted fluorescent in vivo imaging probe that can be used to image CA IX overexpression in response to hypoxia. Oxygen deprivation is associated with several disease states including angiogenisis, pulmonary disease, inflammation, and cancer.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
In cancer, hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. IVISense Hypoxia CA IX 680 fluorescent imaging probe detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors. Pairing IVISense Hypoxia CA IX 680 agent with optical fluorescent imaging technology allows you to image and quantitate tumor sub-regions undergoing hypoxia-related changes, non-invasively and in vivo.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Arthritis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense detects the tumor cell surface expression of carbonic,anhydrase 9 (CA IX) protein, which increases in hypoxic regions,within many tumors, especially in cervical, colorectal, non-small,cell lung tumors. Pairing HypoxiSense with optical fluorescent,imaging technology allows you to image and quantitate tumor,sub-regions undergoing hypoxia-related changes, non-invasively,and in vivo.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.